Skip to main content
. 2024 Sep 15;16(9):4466–4478. doi: 10.62347/RRZF5229

Figure 4.

Figure 4

The CB2 antagonist AM630 blocked esketamine-induced CB2 protein upregulation in LPS-stimulated microglia. Immunocytochemistry staining and western blotting were used to determine microglial CB2 receptor levels, and the cell injury was assessed by using the MTT assay. A. Immunocytochemistry results of CB2 expression (magnification: 40×10). B. Western blot results of microglial CB2 expression (n = 4). C. Microglial viability (n = 10). *: P < 0.05; NS: no significance.